A few months ago, Cele Abad-Zapatero visited our lab here at the EMBL-EBI, he touched all our lives in many ways and was a pleasure to have around. The sort of lab visitor anyone would welcome! Anyway, while here, we worked together on Cele's long-standing idea of an 'atlas' representation of target-chemical space, and a variety of descriptors will be incorporated into the ChEMBL database over the next few releases, both for visualisation, and also to enable data mining.
%J Drug Discovery Today
%T Efficiency Indices for an Effective Mapping of Chemico-biological Space: The Concept of an Atlas-like Representation
%D 2010
%V 15
%P 804-811
%A Abad-Zapatero C.
%A Perišić O.
%A Wass J.
%A Bento A.P.
%A Overington J.
%A Al-Lazikani B.
%A Johnson M.E.
You can be entered into a prize draw where you could win an iPad.
This survey is collecting input from users and potential users of the EBI services. We really value this input for development of our services, and want as many responses as possible. We apologise if, in our enthusiasm, we have contacted you multiple times. Please ignore the multiple contacts and forgive us!
Otherwise, please visit http://www.surveymonkey.com/s/EMBL-EBI and complete the questions relevant to you. We will be collecting data until the end of September.
Kinase SARfari compound and bioactivity data has been updated using the latest release from the ChEMBL database. The compound count has increased from 28,223 to 33,559 and the bioactivity count increased from 146,865 to 212,735.
The September 2010 USANs have just been published, these are:
algenpantucel-L
Whole cell immunotherapy
therapeutic
n/a
amatuximab
MORAb-009
monoclonal antibody
therapeutic
mesothelin
arbaclofen
STX-209
small molecule
therapeutic
GABA B receptor
atopaxar
ER-172594-00, E-5555
small molecule
therapeutic
PAR-1
atopaxar hydrobromide
E-5555, ER-172594-06
small molecule
therapeutic
PAR-1
avagacestat
BMS-708163-01
small molecule
therapeutic
gamma-secretase
carlumab
CNT0-888
monoclonal antibody
therapeutic
MCP-1
danoprevir sodium
RO-5190591-001, R-7227, ITMN-191
small molecule
therapeutic
HCV NS3 proteinase
edivoxetine
LY-2216684
small molecule
therapeutic
NET
enavatuzumab
PDL-192
monoclonal antibody
therapeutic
CD266
erteberel
LY-500307
small molecule
therapeutic
fulranumab
JNJ-42160443, AMG-403
monoclonal antibody
therapeutic
beta-NGF
icrucumab
IMC-18F1
monoclonal antibody
therapeutic
FLT-1
levoglucose
FM-602
sugar
n/a
linsitinib
OSI-906
small molecule
therapeutic
IGF1R
mogamulizumab
KW-0761, KM-8761
monoclonal antibody
therapeutic
CCR4
pegsiticase
Uricase-PEG 20
enzyme
therapeutic
n/a
plecanatide
SP-304
peptide
therapeutic
Guanylyl cyclase receptor-C
ponatinib
AP-24534
small molecule
therapeutic
ABL1 FLT3 VEGFR FGFR TIE2
ponatinib hydrochloride
AP-24534
small molecule
therapeutic
ABL1 FLT3 VEGFR FGFR TIE2
quizartinib
AC-220, AC-010220
small molecule
therapeutic
KIT CSF1R FLT3 PDGFRa PDGFRb RET
quizartinib dihydrochloride
AC-220, AC-010220
small molecule
therapeutic
KIT CSF1R FLT3 PDGFRa PDGFRb RET
solithromycin
CEM-101, OP-1068
natural product
therapeutic
50S Ribosomal Protein
simenepag
AGN-210676
small molecule
therapeutic
Non-Prostanoid Prostaglandin receptor
talminogene laherparepvec
JS1 34.5-hGMCSF 47- pA-
virus
therapeutic
n/a
tofogliflozin
CSG-452
small molecule
therapeutic
SGLT2
urelumab
BMS-663513
monoclonal antibody
therapeutic
CD137
vosaroxin
SNS-595
small molecule
therapeutic
TOP2
As you will see there is a bumper crop this month of new USANs. Lots of monoclonal antibodies and kinase inhibitors (although these are seen as both the parent and salt for in many cases).
We have a special visitor to the EMBL-EBI on Wednesday 10th of November - Didier Rognan of the University of Strasbourg at Illkirch. His presentation, on the "Development and Applications of Computational Chemogenomics" will be after lunch, so if anyone in the Cambridge area is interested in attending (campus staff will get a mail closer to the date, so please don't mail ;) ), please let me know (since I need to get you through security).
One of the great things about large meetings (I'm at the 50th meeting of ICAAC at the moment) are the publisher's stalls; the sort of specialist literature I like doesn't make conventional bookshops, and how bad is Amazon for recommendations for actually surprising and expanding your horizons and interests....
Anyway, we all have a little special someone in our lives, and this book, Germ Stories, is just for them. A set of delightful poems and rhymes about bugs, of all sorts, written by Arthur Kornberg for his children. Education and entertainment for youngsters at it's best. High production values in the book - good quality binding, nice relief printed titling on the dust jacket, and delightful illustrations. A stylistic merging of Dr. Seuss with interesting subject matter, but in no sense is this nonsense. A must buy for all parents - especially at the show price of $20!
%T Germ Stories
%A A. Kornberg
%D 2008
%I University Science Books
%O ISBN-978-1-891389-51-1
Registration in now open for applicants to the EMBL International Phd Programme (EIPP) for an October 2011 intake. We have potentially two positions available in the group, covering our general research interests, or an alternative project of your design. Students will be registered at the University of Cambridge, the highest rated university in the world (according to the QS World University Rankings 2010). Deadline for registration is December 1st 2010.
It is impossible to underestimate the importance of drug discovery researcher community groups in the advance of drug discovery science in general, professional networking, and precompetitive and collaborative activities. A prime example is the UK QSAR and Chemoinformatics Group, who have been in existence since 1986. It is therefore a pleasure to host the Autumn 2010 meeting here at the EMBL-EBI, on Tuesday 12th October 2010 (there will be an informal meal, the evening before at a local hostelry for those interested). Finally, you don't have to work in the UK to attend!
Registration (which is free) is now open at this link.
Would you consider completing the European Bioinformatics Institute (EBI) Survey at: http://www.surveymonkey.com/s/EMBL-EBI
Kinase SARfari compound and bioactivity data has been updated using the latest release from the ChEMBL database. The compound count has increased from 28,223 to 33,559 and the bioactivity count increased from 146,865 to 212,735.
Registration in now open for applicants to the EMBL International Phd Programme (EIPP) for an October 2011 intake. We have potentially two positions available in the group, covering our general research interests, or an alternative project of your design. Students will be registered at the University of Cambridge, the highest rated university in the world (according to the QS World University Rankings 2010). Deadline for registration is December 1st 2010.
